Zai Lab Limited (HKG:9688)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 16.45B -33.8% |
| Revenue (ttm) | 3.55B +8.4% |
| Net Income | -1.40B |
| EPS | -12.67 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,377,300 |
| Open | 14.49 |
| Previous Close | 14.32 |
| Day's Range | 14.08 - 14.56 |
| 52-Week Range | 12.31 - 35.50 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 20.95 (+48.48%) |
| Earnings Date | May 7, 2026 |
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]
Financial Performance
In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.
Financial numbers in USD Financial StatementsNews
Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments
Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments
Zai Lab announces departure of COO Josh Smiley
Zai Lab (ZLAB) announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh…
Zai Lab Announces Changes to Senior Leadership Team
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and effici...
Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB)
Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB)
Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment
Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment
Zai Lab receives FDA Fast Track Designation for zocilurtatug pelitecan
Zai Lab (ZLAB) announced the U.S. Food and Drug Administration has granted Fast Track Designation to zocilurtatug pelitecan, the Company’s potential first-in-class Delta-like ligand 3-targeting antibo...
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug ...
Zai Lab Q1 Earnings Call Highlights
Zai Lab NASDAQ: ZLAB reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology a...
Zai Lab price target lowered to $44 from $47 at Citi
Citi lowered the firm’s price target on Zai Lab (ZLAB) to $44 from $47 and keeps a Buy rating on the shares. The firm updated the company’s model post the
Zai Lab (ZLAB) Highlights Strategic Developments and Future Outlook
Zai Lab (ZLAB) Highlights Strategic Developments and Future Outlook
Zai Lab Q1 2026 Loss Widens to -$0.05/Share, Revenue Down 6%
In-line quarter. Zai Lab Limited (NASDAQ:ZLAB) posted a Q1 2026 loss per share of $0.05, matching the expected loss of $0.05, though the company faced headw... The post Zai Lab Q1 2026 Loss Widens to ...
Zai Lab Earnings Call Transcript: Q1 2026
Q1 revenue declined 6% year-over-year to $99.6M, with near-term pressure expected through 2026 and a return to growth in 2027. Pipeline advances include strong zoci data, new collaborations, and upcoming launches, supported by a robust cash position.
Zai Lab Earnings release: Q1 2026
Zai Lab released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Zai Lab Quarterly report: Q1 2026
Zai Lab has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zai Lab Slides: Q1 2026
Zai Lab has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zai Lab reports Q1 EPS (4c), consensus (53c)
Reports Q1 revenue $99.6M, consensus $108.43M. “We continue to accelerate the development of our global pipeline, with numerous clinical trials underway across oncology and immunology,” said CEO Saman...
Zai Lab Releases Q1 2026 Financial Results
Zai Lab Limited reported a net loss of $51. The post Zai Lab Releases Q1 2026 Financial Results first appeared on Alphastreet .
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corpo...
Zai Lab Proxy statement: Proxy filing
Zai Lab filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Zai Lab Proxy statement: Proxy filing
Zai Lab filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent corporate updat...
Zai Lab Transcript: Study update
Zoci demonstrated high intracranial response rates and durable efficacy in small cell lung cancer with brain metastases, as well as meaningful activity in extrapulmonary neuroendocrine carcinomas, regardless of DLL3 status. Ongoing trials and new combinations aim to establish zoci as a backbone therapy across these indications.
Zai Lab Slides: Study update
Zai Lab has posted slides in relation to its latest quarterly earnings report, which was published on April 20, 2026.
ZLAB: Zai Lab Unveils Promising Data for ZL-1503 in Treating Atopic Diseases
ZLAB: Zai Lab Unveils Promising Data for ZL-1503 in Treating Atopic Diseases
Zai Lab presents new preclinical data on ZL-1503
Zai Lab (ZLAB) Limited announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Ralpha bispecific antibody may lead to sustained suppres...